Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review.
Hormones (Athens)
; 9(3): 274-8, 2010.
Article
em En
| MEDLINE
| ID: mdl-20688626
ABSTRACT
X-linked dominant hypophosphatemic rickets (XLH) is the most prevalent genetic form of hypophosphatemic rickets. Standard treatment of XLH patients includes long-term administration of phosphate and calcitriol. Treated patients usually respond well to the conventional therapy and demonstrate amelioration of rachitic symptoms and improved growth. However, long-term administration of phosphate and vitamin D preparations is sometimes complicated with nephrocalcinosis, secondary or tertiary hyperparathyroidism and arterial hypertension. We describe a patient with XLH, caused by a rare missense mutation of the PHEX gene. The patient, while under treatment with alphacalcidol and oral phosphate, developed hypercalciuria, nephrocalcinosis, secondary hyperparathyroidism and arterial hypertension. Cinacalcet was added to the therapeutic regimen and the long-term effects on calciotropic parameters and FGF23 levels are herein reported.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Fosfatos
/
Doenças Genéticas Ligadas ao Cromossomo X
/
Conservadores da Densidade Óssea
/
Raquitismo Hipofosfatêmico Familiar
/
Hidroxicolecalciferóis
/
Hiperparatireoidismo Secundário
/
Naftalenos
Limite:
Adult
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2010
Tipo de documento:
Article